History
MILESTONE
TIME
2015
SBIR funding Phase II:the production technology development for High-potency Doxorubicin 2015 Jan: pass ISO-9001
2013
SBIR funding Phase I:the production technology development for High-potency Doxorubicin
2012
December: Logon Emerging trading.
November: Public offer approved.
60 tons fermenter was put in production.
2011
Ministry of Economic Affairs funding:the production technology development for API Daptomycin
2010
Organizational restructuring, new management team stationed.
SBIR funding: the production technology development for API Pristinamycin
2009
Republic of China 98 SBIR : Outstanding industry contribution award
ISO-9001:2008 Certificate
2006
Taiwan SBIR funding: the production technology development for API Natamycin
50 tons fermenter was put in production
2004
Industrial production of API intermediate Mycophenolic Acid crude
2003
ISO-9001:2000 Certificate
2002
30 tons fermenter was put in production
2001
Drug manufacturers factory registration certificate
Set up a comprehensive quality management standardization
Taiwan SBIR funding: the production technology development for API Acarbose
2000
The plant in ChiaYi was set up.
Company was founded.